Date published: 2026-8-13

1-800-457-3801

SCBT Portrait Logo
Seach Input

fibrillin-1 CRISPR/Cas9 KO Plasmid (m): sc-420296

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • fibrillin-1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the fibrillin-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    fibrillin-1 CRISPR/Cas9 KO Plasmid (m)

    sc-420296
    20 µg
    $397.00

    Overview

    Mouse Fbn1 encodes fibrillin-1, a major extracellular matrix glycoprotein that assembles into microfibrils to provide elastic fiber scaffolding and regulate tissue biomechanics. Fibrillin-1 microfibrils coordinate growth factor bioavailability, particularly by modulating latent TGF-β complex sequestration and signaling outputs that influence vascular, skeletal, and connective tissue homeostasis. Through these matrix–signaling interactions, Fbn1 impacts processes such as extracellular matrix organization, mechanotransduction, and developmental morphogenesis. Disruption of fibrillin-1 function is widely used to model microfibrillopathies and connective tissue phenotypes relevant to cardiovascular remodeling and musculoskeletal integrity in experimental systems.

    fibrillin-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Fbn1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Fbn1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Fbn1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish fibrillin-1 protein expression.

    This CRISPR knockout system enables efficient generation of Fbn1-deficient cell models for investigation of fibrillin-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Fbn1 exon(s) critical for fibrillin-1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Fbn1 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by fibrillin-1 CRISPR/Cas9 KO Plasmid (m) and fibrillin-1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Fbn1 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by fibrillin-1 HDR Plasmid (m) and fibrillin-1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Fbn1 homology arms to support homology-directed repair at defined Fbn1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.